- Home
- COYA vs HLVX Comparison
COYA vs HLVX Comparison
Compare COYA & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- HLVX
- Stock Information
- Founded
- COYA 2020
- HLVX 2020
- Country
- COYA United States
- HLVX United States
- Employees
- COYA N/A
- HLVX N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- HLVX Health Care
- Exchange
- COYA Nasdaq
- HLVX Nasdaq
- Market Cap
- COYA 99.8M
- HLVX 83.7M
- IPO Year
- COYA 2022
- HLVX 2022
- Fundamental
- Price
- COYA $5.80
- HLVX $1.97
- Analyst Decision
- COYA Strong Buy
- HLVX Hold
- Analyst Count
- COYA 3
- HLVX 5
- Target Price
- COYA $16.67
- HLVX $2.33
- AVG Volume (30 Days)
- COYA 52.1K
- HLVX 436.7K
- Earning Date
- COYA 08-11-2025
- HLVX 08-07-2025
- Dividend Yield
- COYA N/A
- HLVX N/A
- EPS Growth
- COYA N/A
- HLVX N/A
- EPS
- COYA N/A
- HLVX N/A
- Revenue
- COYA $3,685,107.00
- HLVX N/A
- Revenue This Year
- COYA $106.97
- HLVX N/A
- Revenue Next Year
- COYA N/A
- HLVX N/A
- P/E Ratio
- COYA N/A
- HLVX N/A
- Revenue Growth
- COYA N/A
- HLVX N/A
- 52 Week Low
- COYA $4.65
- HLVX $1.34
- 52 Week High
- COYA $10.24
- HLVX $15.25
- Technical
- Relative Strength Index (RSI)
- COYA 55.18
- HLVX 58.49
- Support Level
- COYA $5.61
- HLVX $1.83
- Resistance Level
- COYA $5.87
- HLVX $1.95
- Average True Range (ATR)
- COYA 0.37
- HLVX 0.08
- MACD
- COYA 0.05
- HLVX 0.00
- Stochastic Oscillator
- COYA 67.51
- HLVX 60.78
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.